- Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), a leading international forum for early-phase oncology drug development.
- First-in-class FGFR3 ADC: BHV-1530 is a first-in-class potential FGFR3-directed antibody-drug conjugate incorporating Biohaven's proprietary TopoIx payload, that has shown early clinical activity with a differentiated and tolerable safety profile.
- Anti-PD-1 combination now enrolling: Under its clinical supply agreement with Regeneron Pharmaceuticals, Inc., Biohaven has begun enrollment, evaluating BHV-1530 in combination with cemiplimab (Libtayo).
NEW HAVEN, Conn., Sept. 28, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), to be held November 18-20, 2026, at the CCIB in Barcelona, Spain.
Selection for an oral presentation at the EORTC-NCI-AACR Symposium, one of the foremost venues for molecular-targeted and early-phase cancer therapeutics, underscores the scientific interest in FGFR3 as a therapeutic target and in Biohaven's TopoIx ADC platform. Early clinical activity has been observed, including confirmed partial responses in heavily pretreated patients, as previously disclosed. The data have shown a favorable and differentiated safety profile, with no dose-limiting toxicities and no FGFR inhibitor-class toxicities, such as hyperphosphatemia, nail disorders, stomatitis, or retinopathy, that commonly constrain dosing and duration of approved FGFR tyrosine kinase inhibitors.